Skip to main content

Table 3 Characteristics of the subgroups with a disease duration < or ≥ 10 years

From: Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study

CategoryNo. (%)p-value
dd < 10a
(n = 17)
dd ≥ 10a
(n = 35)
Group
 Control n (%)8 (47.1)20 (57.1)0,56a
 Intervention n (%)9 (52.9)15 (42.9)
Gender
 Female n (%)8 (47.1)11 (31.4)0,36a
 Male n (%)9 (52.9)24 (68.6)
Age
 Mean (SD)40.76 (15.35)49.37 (9.19)0,0148b
 Median (25%; 75%)44.0 (24.5; 53.5)51.0 (44.0; 57.0)
Self-reported BSA
 Mean (SD)3.69 (2.7)10.79 (20.83)0,79c
 Median (25%; 75%)4.0 (2.0; 4.0)2.0 (0.3; 10.0)
DLQI
 Mean (SD)7.82 (6.01)5.8 (7.39)0,06c
 Median (25%; 75%)6.0 (2.5; 12.5)3.0 (1.0; 9.0)
Disease duration
 Mean (SD)5.59 (2.96)24.23 (11.1)P < 0.0001b
 Median (25%; 75%)5.0 (3.5; 9.0)20.0 (15.0; 31.0)
BMI
 Mean (SD)29.19 (7.85)29.10 (5.53)0,49c
 Median (25%; 75%)26.9 (23.5; 32.5)27.8 (24.8; 32.8)
Comorbidity
 Psoriatic arthritis, n (%)3 (17.6)15 (42.9)0,12a
 Depression, n (%)2 (11.8)9 (26.5)0,30a
 Allergy, n (%)5 (29.4)12 (35.3)0,76a
 Hypertension, n (%)7 (41.2)11 (32.4)0,55a
 Cardiovascular diseases, n (%)03 (8.8)0,54a
 Hypercholesterolemia, n (%)5 (29.4)6 (17.6)0,47a
 COPD, asthma, n (%)2 (11.8)7 (20.6)0,70a
 Hepatitis, cirrhosis of the liver, other liver diseases, n (%)03 (8.8)0,54a
 Diabetes mellitus, n (%)05 (14.7)0,16a
 Cancer, n (%)01 (2.9)1,00a
 No comorbidities, n (%)5 (29.4)9 (26.5)1,00a
 Current smoker, n (%)8 (47.1)12 (36.4)0,55a
 Ex-smoker, n (%)6 (35.3)16 (48.5)0,55a
 Non-smoker, n (%)3 (17.6)11 (33.3)0,33a
  1. aFisher’s exact test; bunpaired t-test; cMann-Whitney test; a age, BMI Body-Mass-Index, BSA Body Surface Area (range: 0–100), COPD Chronic obstructive pulmonary disease, dd disease duration, DLQI Dermatology Life Quality Index, n number, SD standard deviation, 25% 25th percentile, 75% 75th percentile
  2. Significant p values (p<0,05) are written in boldface